Current and future disease-modifying therapies in multiple sclerosis.
about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsMultiple sclerosis: the role of cytokines in pathogenesis and in therapiesPI3Kγ drives priming and survival of autoreactive CD4(+) T cells during experimental autoimmune encephalomyelitis.Heterogeneity versus homogeneity of multiple sclerosis.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.The dynamics of mucosal-associated invariant T cells in multiple sclerosis.A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.The role of natural killer cells in multiple sclerosis and their therapeutic implications.Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).Multiple sclerosis: a disorder of altered T-cell homeostasisIncreasing acetyl-CoA metabolism attenuates injury and alters spinal cord lipid content in mice subjected to experimental autoimmune encephalomyelitis.Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface MethodologyTreatment adherence in multiple sclerosis: a survey of Belgian neurologists.Fingolimod exacerbated affective psychosis?Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β.MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice.Analysis of left ventricular function of the mouse heart during experimentally induced hyperthyroidism and recovery.Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.
P2860
Q26830569-E2683650-225C-4805-95A5-2B45A6D0E331Q27011014-4FCCF129-31E3-4E98-8BCF-AFC049582AD5Q34428066-68CEED6C-26D3-4800-9966-9C010871169FQ34893931-C5829025-4DD0-43EA-9E77-631208B7AE42Q35589934-1C663A2E-8691-4FD0-8E76-245B1C02F388Q35606563-A43CCDB7-FE3F-42C9-A6CA-F0207363AA60Q37153260-FA810AEC-1DEA-4BD4-8D4E-5B6A97AF3414Q37818921-EEC4636A-3DF7-46E3-8FEF-B950BD6F8F0FQ38089599-CAEB2A7C-093B-48D6-AC9F-45CE1463581BQ38314584-E60183C9-B6B6-42BC-8889-7DCA6D2B9079Q38760373-1C396C4A-DBBF-475A-B3F8-C9B71C9F4E24Q38859739-7DCC0D7A-EDD5-41F6-A426-ED67531133CEQ39130808-45A3DFDF-5DD4-49A6-8B9C-089E2BF4D8FAQ41442598-C6B3B7A2-3B15-4139-BD13-22401BC07CCAQ42245817-5FCA82F3-16FB-4A64-A9DC-91CE0746EA87Q43603029-AA27620E-A46A-4E3A-87E9-7123BF403D6CQ44072358-EF51FF86-77CF-4CBC-AFCE-C8B1C4DFDF61Q44298506-E1441DF9-7AC6-4B74-A4D2-B400F253C851Q46149675-79F0A743-385C-4D8E-BA7E-08232926EB7BQ47935971-C3B3EBEB-869E-4EC6-A5EE-49CB85F5B1F2Q49997332-35FA43DE-41E0-4FFB-98D1-64FB8E75D648Q51077100-2E0BDDAA-8B79-47DC-B247-667975C4613CQ51240973-F5973C03-9FC3-4D84-94CC-A0EBBD8C5E47
P2860
Current and future disease-modifying therapies in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and future disease-modifying therapies in multiple sclerosis.
@en
Current and future disease-modifying therapies in multiple sclerosis.
@nl
type
label
Current and future disease-modifying therapies in multiple sclerosis.
@en
Current and future disease-modifying therapies in multiple sclerosis.
@nl
prefLabel
Current and future disease-modifying therapies in multiple sclerosis.
@en
Current and future disease-modifying therapies in multiple sclerosis.
@nl
P2860
P1476
Current and future disease-modifying therapies in multiple sclerosis.
@en
P2093
C S Constantinescu
P2860
P304
P356
10.1111/J.1742-1241.2009.02261.X
P577
2010-04-01T00:00:00Z